You are here

  • Home
  • Archive
  • Volume 78, Issue Suppl 2
  • FRI0128 A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) FOR SUBCUTANEOUS ADMINISTRATION: 1-YEAR RESULTS FROM A PART 1 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Friday, 14 June 2019
Rheumatoid arthritis – biological DMARDs
FRI0128 A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) FOR SUBCUTANEOUS ADMINISTRATION: 1-YEAR RESULTS FROM A PART 1 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Free

 

Online download statistics by month:

Online download statistics by month: June 2019 to March 2024

AbstractFullPdf
Jun 201911901025
Jul 201989011
Aug 2019263031
Sep 2019382055
Oct 2019386043
Nov 2019272031
Dec 2019152018
Jan 2020130029
Feb 2020124014
Mar 2020124023
Apr 2020106033
May 202080029
Jun 2020112024
Jul 202074016
Aug 202096012
Sep 202092012
Oct 202096019
Nov 202091012
Dec 20205809
Jan 202169016
Feb 20217808
Mar 20214603
Apr 20215607
May 202117017
Jun 2021007
Jul 20213011
Aug 2021005
Sep 2021209
Oct 202142022
Nov 202173019
Dec 202187015
Jan 20226001
Feb 2022124014
Mar 20225806
Apr 20227006
May 202267012
Jun 20226209
Jul 20225503
Aug 20222703
Sep 202245010
Oct 20224108
Nov 20223409
Dec 20224205
Jan 202370010
Feb 202310101
Mar 20235704
Apr 20234903
May 20233602
Jun 20237505
Jul 20235905
Aug 20236905
Sep 20235107
Oct 20234003
Nov 202310401
Dec 20239003
Jan 20245600
Feb 20243603
Mar 20247206
Total496901729